ClinicalTrials.gg
Not yet recruitingNCT07850089Updated Sep 30, 2026

Postbiotics for GI Recovery After Malignant Bowel Obstruction Surgery

An interventional study of High-Concentration Compound Lactic Acid Bacteria Metabolite JK-5G and Placebo in Age 18 to 80 Years, Malignant Mechanical Bowel Obstruction Diagnosed Clinically/Radiologically, With Prior Abdominal Surgery for Relief and Hemodynamically Stable Within 24h Post-op, Per Investigator, sponsored by First Affiliated Hospital of Wenzhou Medical University. Not yet recruiting. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by First Affiliated Hospital of Wenzhou Medical University · Not applicable, Interventional, and Treatment

How we know

Updated Sep 30, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Objective: To evaluate the effects of the postbiotic preparation JK-5G on gastrointestinal function recovery (GI-2 time), gastrointestinal dysfunction, nutritional status, and safety in patients after surgery for malignant bowel obstruction.

Design: A randomized, double-blind, placebo-controlled, exploratory clinical trial. Patients are randomized 1:1 within 24 hours after surgery. After meeting criteria for initiating enteral intake, they receive either JK-5G or placebo (one sachet three times daily) for 10 consecutive days, and are followed up to postoperative day 30.

Study Population: Adult patients (18-80 years old) who undergo surgery for malignant mechanical bowel obstruction and are hemodynamically stable within 24 hours after surgery.

Sample Size: A total of 80 patients (40 in the postbiotic group and 40 in the placebo group). A blinded review of variability will be conducted after 40 patients have completed the study.

Primary Endpoint: Time from the end of surgery to GI-2 recovery, where GI-2 recovery is defined as the later of the following two events: first passage of stool/effective stoma output, and first tolerance of the target diet. Key secondary endpoints include daily I-FEED scores, incidence of prolonged postoperative ileus, achievement of nutritional targets, and safety events.

Statistics and Timeline: The primary analysis will use a stratified Cox model (intention-to-treat principle). The study is planned to be conducted from September 2026 to February 2028.

Read the detailed description

Project Title: A Randomized, Double-Blind, Placebo-Controlled Exploratory Clinical Trial of Highly Concentrated Compound Lactic Acid Bacteria Metabolites JK-5G for Promoting Gastrointestinal Function Recovery After Surgery for Malignant Bowel Obstruction Study Objective: To evaluate the effects of JK-5G on GI-2 recovery time, gastrointestinal dysfunction, nutritional recovery, and safety after surgery for malignant bowel obstruction Study Population: Adult patients who undergo surgery for malignant mechanical bowel obstruction and are haemodynamically stable within 24 hours after surgery Sample Size: Exploratory sample size of 80 cases (40 in the postbiotic group and 40 in the placebo group); a blinded variability review will be conducted after 40 patients have completed the study Inclusion Criteria: Aged 18-80 years; diagnosed with malignant-related mechanical bowel obstruction and have undergone surgery to relieve the obstruction; stable within 24 hours after surgery; informed consent signed Exclusion Criteria Residual mechanical obstruction or planned re-operation; short bowel syndrome/severe intestinal fistula; haemodynamic instability requiring continuous circulatory or respiratory support; allergy to the product; inability to discontinue other microecological preparations; pregnancy or lactation; concurrent participation in another interventional clinical trial; etc.

Trial Design: 1:1 randomised, double-blind, placebo-controlled within 24 hours after surgery; after reaching the criteria for initiating enteral intake, patients receive either JK-5G or placebo (one sachet three times daily) for 10 consecutive days; those who do not start the intervention continue to be followed up and are included in the ITT analysis Endpoint Measures: Primary endpoint: time from end of surgery to GI-2 recovery. Key secondary endpoints: daily I-FEED score, prolonged postoperative ileus, achievement of nutritional targets, and safety events. Other secondary endpoints include gastrointestinal recovery, hospitalisation, and 30-day outcomes Statistical Analysis: Primary analysis uses a stratified Cox model, reporting hazard ratios and 95% confidence intervals; ITT is the primary analysis, supported by per-protocol and safety sets; pre-specified sensitivity analyses for death, re-operation, and missing data Study Duration: Each patient is followed up to postoperative day 30; the overall study is planned from September 2026 to February 2028

02

Conditions studied

  • Age 18 to 80 Years
  • Malignant Mechanical Bowel Obstruction Diagnosed Clinically/Radiologically, With Prior Abdominal Surgery for Relief
  • Hemodynamically Stable Within 24h Post-op, Per Investigator
  • Informed Consent Obtained Before Surgery or Randomization
03

In context

Lead sponsor

First Affiliated Hospital of Wenzhou Medical University is the lead sponsor of 83 studies on the registry; 57 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects must meet all of the following criteria to be enrolled:

  1. Age 18-80 years.
  2. Diagnosed with malignant mechanical bowel obstruction based on clinical and imaging findings, and have undergone abdominal surgery for the purpose of relieving the obstruction.
  3. Vital signs are stable within 24 hours after surgery, and the investigator judges that the subject can continue to participate in the trial.
  4. Written has been signed by the subject or their legally authorized representative before surgery or before randomization.

Exclusion criteria

Exclusion Criteria:

Subjects meeting any of the following criteria will not be enrolled:

  1. Presence of unresolved mechanical obstruction after surgery, or planned re-laparotomy in the short term.
  2. Short bowel syndrome or severe intestinal fistula.
  3. Persistent hemodynamic instability requiring continuous vasopressors or mechanical ventilation after surgery, or severe hepatic/renal failure that, in the investigator's opinion, makes enteral intervention inappropriate.
  4. Allergy to any component of the postbiotic preparation.
  5. Continuous use of other probiotics, prebiotics, synbiotics, or postbiotics within 2 weeks prior to randomization and inability to discontinue them; perioperative prophylactic or therapeutic antibiotics are not exclusion criteria but must be fully documented.
  6. Pregnancy or lactation.
  7. Concurrent participation in another interventional clinical trial.
  8. Any other condition that, in the investigator's judgment, makes the subject unsuitable for enrollment.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Experimental group

    Drug: High-Concentration Compound Lactic Acid Bacteria Metabolite JK-5G

  • Placebo comparator
    control group

    Drug: Placebo

Interventions

  • DrugHigh-Concentration Compound Lactic Acid Bacteria Metabolite JK-5G

    Highly concentrated compound lactic acid bacteria metabolites JK-5G is mainly composed of inactivated lactic acid bacterial strains (such as Lactococcus lactis, approximately 21 species of Lactobacillus, etc.) and their bioactive metabolites. Its important components include short-chain fatty acids (SCFAs) and inactivated lactic acid bacteria.

  • DrugPlacebo

    The placebo is completely identical to JK-5G in appearance, color, particle size, taste, odor, packaging, labeling, and reconstitution characteristics. It does not contain lactic acid bacteria metabolites, live bacteria, inactivated bacterial cells, or any other ingredients with known microecological activity.

06

What researchers measure

Primary outcomes

  1. Time from surgery end to GI-2 recovery.

    GI-2 is defined as the later of the following two events: (1) first passage of stool; in patients with a stoma, the first clinically meaningful spontaneous stoma output, excluding mere bloody fluid, irrigant, or mucus; and (2) first tolerance of the protocol-specified target diet, with no return to fasting/clear fluids only due to nausea, vomiting, or abdominal distension within the subsequent 24 hours, and no need for reinsertion of nasogastric decompression. The primary endpoint will be adjudicated by an outcome assessor who is independent of the clinical treatment decisions.

    Time frame: From the end of surgery until GI-2 recovery, assessed up to 30 days after surgery

Secondary outcomes

  1. Daily I-FEED

    Daily assessment from day 1 to 10 after surgery. An I-FEED score of 0-2 means normal recovery, 3-5 means gastrointestinal intolerance, and ≥6 means gastrointestinal dysfunction.

    Time frame: Postoperative day 1 to 10

  2. Prolonged Postoperative Ileus

    Presence of at least 2 of the following 5 criteria on or after postoperative day 4, after excluding mechanical obstruction or other identifiable causes: ① nausea/vomiting within the past 24 hours; ② inability to tolerate oral/enteral feeding; ③ no passage of flatus or stool within the past 24 hours; ④ abdominal distension; ⑤ radiological findings supportive of ileus.

    Time frame: On or after postoperative day 4

  3. Nutritional Goal Attainment

    Achievement of ≥60% of target energy intake on postoperative day 5. Additionally, the time to reaching ≥80% of target energy intake, daily energy/protein intake, and number of days on parenteral nutrition will be recorded.

    Time frame: Postoperative day 5, up to 30 days

  4. Safety Events

    Adverse events (AEs) and serious adverse events (SAEs) during the treatment period, CTCAE grading, discontinuation of study product, as well as anastomotic leakage, intra-abdominal infection, surgical site infection, diarrhoea, abdominal pain, nausea/vomiting, and 30-day mortality.

    Time frame: From baseline through 30 days after surgery

07

Study locations

No study locations are listed for this record.

08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2026; primary completion for Feb 2028, 17 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2026
First posted
Sep 30, 2026
StartEst.
Sep 2026
Primary completionEst.
Feb 2028
CompletionEst.
Sep 2028
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07850089
Lead sponsor
First Affiliated Hospital of Wenzhou Medical University
Responsible party
Sponsor
First posted
Sep 30, 2026
Start date
Sep 2026 (estimated)
Primary completion
Feb 2028 (estimated)
Completion
Sep 2028 (estimated)
Last update
Sep 30, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion